M.D. Anderson Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, M.D. Anderson Cancer Center sits in the top decile of US sponsors by registered trial count (#3 of 15,751 sponsors by registered trial count).
M.D. Anderson Cancer Center: 2,692 sponsored US clinical trials, 549 recruiting.
M.D. Anderson Cancer Center sponsors 2,692 registered US clinical trials on ClinicalTrials.gov, 549 of them currently recruiting, and 1,201 completed. 124 of these trials are in Phase 3-4 (later-stage) and 1,719 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hematopoietic and Lymphoid Cell Neoplasm, with 44 trials.
Top-decile sponsor footprint
M.D. Anderson Cancer Center ranks in the top decile of sponsors by registered trial count (#3 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
2,692 total, page 38 of 54
Combining Varenicline and Bupropion for Smoking Cessation
NCT00943618
Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC)
NCT01122615
Ipilimumab + Temozolomide in Metastatic Melanoma
NCT01119508
Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies
NCT01113476
Fludarabine, Bendamustine, and Rituximab (FBR) for Relapsed Chronic Lymphocytic Leukemia (CLL)
NCT01096992
Conservative Surgery in Treating Patients With Low-Risk Stage IA2 or IB1 Cervical Cancer
NCT01048853
First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
NCT01097746
TKI258 in Castrate Resistant Prostate Cancer
NCT00831792
Lung Cancer STARS Trial - STARS Revised Clinical Trial Protocol: Stereotactic Ablative Radiotherapy (SABR) in Stage I Non-small Cell Lung Cancer Patients Who Can Undergo Lobectomy
NCT02357992
Pleural Catheters Versus Thoracoscopic Pleurodesis
NCT01117740
Caphosol in Sarcoma Patients With Mucositis
NCT00965172
Simultaneous Integrated Boost (SIB) in Esophageal Cancer
NCT01102088
Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients
NCT00966277
TPI 287 in Patients With Recurrent Glioblastoma Multiforme
NCT01113463
Fluorescent Dyes for Lymph Node Mapping
NCT01095913
Lapatinib With Sirolimus or Metformin
NCT01087983
Lenalidomide and High-Dose Melphalan
NCT01079936
Eltrombopag for Post Transplant Thrombocytopenia
NCT01000051
Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
NCT01064479
A Phase I Study of TPI 287 - Temozolomide Combination in Melanoma
NCT01067066
Study of Total Skin Electron Beam Therapy (TSEBT) in Stage IB-IIIA Mycosis Fungoides
NCT01073267
Phase II Study of Tesetaxel in Metastatic Melanoma
NCT01064713
Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT01002755
Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM)
NCT01067469
Clofarabine, Idarubicin, and Cytarabine Combination in Acute Myeloid Leukemia (AML) Induction
NCT01025154
Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS)
NCT00903760
Docetaxel and Sirolimus in Patients With Advanced Malignancies
NCT01054313
Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma
NCT00904722
HAI Abraxane With Gemcitabine and Bevacizumab
NCT01057264
M. D. Anderson Symptom Inventory - Ovarian Cancer
NCT01037751
Detection of Cervical Lymph Node Metastases With a High-Resolution Positron Emission Tomography (PET) Imaging System
NCT01030497
Feasibility Study for Imaging of Peripheral Tumors With a High-Resolution PET Imaging System
NCT01008930
Comparison of PEM Uptake Value (PUV) and Standardized Uptake Value (SUV) in Patients With Malignancies of the Breast
NCT01031238
Chlorhexidine Gel Therapy for Cariogenic Oral Microflora
NCT01036412
5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
NCT01038635
Study of Weekly LOC-paclitaxel Injection for Melanoma
NCT01039844
Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide
NCT01010217
RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia
NCT00968253
Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory Lymphoma
NCT00967044
Ondansetron Versus Aprepitant Plus Ondansetron for Emesis
NCT00954941
Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies
NCT01015222
Patient-Reported Outcomes-Based Palliative and Hospice Care Practice: A Usability Study
NCT01024166
Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
NCT01019317
Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer
NCT00903006
Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation
NCT00990249
Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
NCT00948064
Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma
NCT00970996
Pharmacokinetics of Posaconazole Prophylaxis in Acute Leukemia
NCT00936117
Testosterone Replacement for Fatigue in Male Hypogonadic Advanced Cancer Patients
NCT00965341
Determinants of Smoking Cessation Among Latinos
NCT01008748
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 748 |
| Phase 2 | 971 |
| Phase 3 | 96 |
| Phase 4 | 28 |
Therapeutic Areas
What is open in the M.D. Anderson Cancer Center pipeline
549 recruiting of 2,692 indexed (20% open); 1,201 completed (45%).
Phase mix: 124 late (III/IV) vs 1,719 early (I/II) (early-phase heavy).
Top condition: Hematopoietic and Lymphoid Cell Neoplasm (44 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.